| Document |
Document Title |
|
WO/2018/008647A1 |
The present invention provides a method for detecting fucose analogue and sugar. The present invention provides, for example, a compound represented by general formula (I) or a salt thereof: (I) {In the formula, L is -(CH2)n- and n is an...
|
|
WO/2018/009623A1 |
A compound or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to a virus of the Paramyxoviridae or Orthomyxoviridae family, or other disorders, in particular respiratory sync...
|
|
WO/2018/002739A1 |
The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, form...
|
|
WO/2018/001393A1 |
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use The invention provides a new group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, wherein R is defined in the claims. The compounds of ...
|
|
WO/2017/223020A1 |
The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R1, R2 and R3 are as defined herein. The present invention also relat...
|
|
WO/2017/219510A1 |
A quinoid chalcone c-glycoside dimer compound having an anti-tumor activity and an anti-inflammatory activity and a method for preparing same. The compound is a quinoid chalcone c-glycoside dimer compound separated from Carthamus tinctor...
|
|
WO/2017/221083A1 |
The compositions and compounds of formula I which includes ribavirin conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmac...
|
|
WO/2017/223421A1 |
Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives o...
|
|
WO/2017/221929A1 |
The present invention pertains to a method for synthesizing a ribonucleic acid H-phosphonate monomer, and a method for performing oligonucleotide synthesis in which said monomer is used. The present invention pertains to a method for man...
|
|
WO/2017/223012A1 |
The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates...
|
|
WO/2017/223474A1 |
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associ...
|
|
WO/2017/223024A1 |
The present invention relates to methods of treating or preventing a viral infection using Compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein A, B, R1, R2, R3, Q and V are as defined herein. The present inve...
|
|
WO/2017/218802A1 |
The disclosure is directed to compounds of Formula (I) and Formula (II). Methods of their use and preparation is other described.
|
|
WO/2017/218580A1 |
The present application is directed to methods of making a pharmaceutically acceptable salt of nicotinamide riboside and related compounds by alkylating nicotinamide with a 1-chloro-D-ribofuranose derivative. The present invention relate...
|
|
WO/2017/214112A1 |
Described are 5'-cyclo-phosphonate modified nucleotides, and oligonucleotides, such as interference (RNAi) agents, containing 5'-cyclo-phosphonate modified nucleotides. The RNAi agents having either double-stranded or single-stranded oli...
|
|
WO/2017/207986A1 |
This invention relates to derivatives of cladribine of Formula (I). The compounds are phosphoramidate derivatives in which the phosphoramidate moiety is situated on the 3'-hydroxyl group of cladribine. The invention also relates to pharm...
|
|
WO/2017/210611A1 |
Described herein are bisphosphonate quinolone conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein...
|
|
WO/2017/207989A1 |
The present invention relates to chemical compounds of formula (I) as defined in the amended claims, their preparation and their use in the treatment of cancer.
|
|
WO/2017/207754A1 |
The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.
|
|
WO/2017/203395A1 |
The present invention relates to novel crystalline forms of L-alanine,N-[(S)-[[(lR)-2-(6- amino-9H-purin-9-yl)-1methylethoxy]methyl]phenoxyphosphinyl]
-1-methylethyl ester, (2E)- 2-butenedioate or Tenofovir Alafenamide hemi fumarate(I). ...
|
|
WO/2017/204583A1 |
The present invention relates to a composition for inducing transformation of non-neuronal cells into induced neural stem cells, a kit, for inducing transformation of non-neuronal cells into induced neural stem cells, comprising the comp...
|
|
WO/2017/205336A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of thereof in the sequencing a nucleic acid.
|
|
WO/2017/198775A1 |
The present invention relates to chiral phosphoramidites represented by formula (Ia) or formula (Ib) as novel monomers for the synthesis of stereodefined phosphorothioate MOE oligonucleotides. Furthermore, the present invention relates t...
|
|
WO/2017/199028A1 |
A method of preparing an active agent or a salt thereof from a prodrug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond betw...
|
|
WO/2017/194498A1 |
The present invention relates to the field of stereodefined phosphorothioate oligonucleotides and to stereodefining nucleoside monomers and methods of synthesis of stereodefined oligonucleotides. Herein are disclosed solvent compositions...
|
|
WO/2017/196697A1 |
This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.
|
|
WO/2017/190715A1 |
The invention relates to a preparation method of an amorphous form of sofosbuvir of formula I, (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2
H)-yl)-4- fluoro-3-hydroxy-4-memyltetrahydrofuran-2-yl)methoxy)-(ph...
|
|
WO/2017/189978A1 |
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...
|
|
WO/2017/185549A1 |
Provided is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, ATP, and ribose react under the catalytic effects of nicotinamide phosphoribosyltransferase, phosphoribose pyrophosphokinase, and ribokinase so a...
|
|
WO/2017/184885A1 |
Compositions are provided including nicotinic acid riboside ("NAR"), and derivatives thereof including l -(2',3 ',5'-triacetyl-beta-D-ribofuranosyl)-nicotinic acid ("NAR triacetate" or "NARTA"); or derivatives of a reduced form of nicoti...
|
|
WO/2017/183217A1 |
[Problem] To provide, as a substitute for a clinically used injected drug (5-azacytidine or 2'-deoxy-5-azacytidine), a 5-azacytidine or 2'-deoxy-5-azacytidine prodrug having high stability against the metabolic enzyme cytidine deaminase,...
|
|
WO/2017/183215A1 |
[Problem] To provide, as a substitute for a clinically used injected drug (5-azacytidine or 2'-deoxy-5-azacytidine), a 5-azacytidine or 2'-deoxy-5-azacytidine prodrug having high stability against the metabolic enzyme cytidine deaminase,...
|
|
WO/2017/184668A1 |
Provided are methods for treating Flaviviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:, wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositi...
|
|
WO/2017/174322A1 |
The present invention relates to the field of powders, particularly food powders, and to the avoidance of caking in such powders by using compositions comprising dehydrated or partially dehydrated disodium inosine monophosphate salts.
|
|
WO/2017/176677A1 |
This invention provides nucleotide analogues each of which comprises a tag comprising one or more Forster resonance energy transfer (FRET) acceptor fluorophores, a nucleotide polymerase having one or more FRET donor fluorophores, and met...
|
|
WO/2017/170348A1 |
Provided are methods, uses, and compositions for treating acute myeloid leukemia which includes therapeutically effective combinations of 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin
-1-yl]phenyl}amino)-5-(tetrahydro-2H-p...
|
|
WO/2017/163186A1 |
The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these...
|
|
WO/2017/162169A1 |
The present invention relates to a uridine phosphoramide prodrug, the preparation method therefor, and the medicinal uses thereof. The prodrug of the present invention is a chemical compound as shown in formula I, an optical isomer there...
|
|
WO/2017/162536A1 |
Prodrugs of vortioxetine are provided
|
|
WO/2017/160855A1 |
The present invention discloses a bone-targeting therapeutic conjugate comprising a formula of TG-M-D (I) or M-D-TG (II) and methods of making and using the same. The present invention also discloses a composition comprising the conjugat...
|
|
WO/2017/157672A1 |
The present invention relates to the field of stereodefined phosphorothioate oligonucleotidess and to nucleoside monomers and methods of synthesis thereof. Herein are disclosed acyl protected L-LNA-G monomers which have improved solubili...
|
|
WO/2017/160672A1 |
Modified Tryptamine, Tryptamine-2'-deoxy-uridine (TrpdU) and TrpdU-phosphoramidites for oligonucleotide synthesis are provided, as well as improved methods of their synthesis and oligonucleotides comprising at least one modified TrpdU nu...
|
|
WO/2017/158624A1 |
The present disclosure provides novel crystalline sofosbuvir form- M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage ...
|
|
WO/2017/161349A1 |
Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
|
|
WO/2017/157356A1 |
Compounds of general formulae6 and 13 where X is -NH-C(NH2)=N+H2 or -N+H3, Y is a linear oligomer consisting of arginine units terminated with an aminodimethylenamide unit (-Arg)n-NH-(CH2)2-NH2, where n = 6-10, or arginine-aminocaproic u...
|
|
WO/2017/160741A1 |
The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.
|
|
WO/2017/160793A1 |
Provided herein a re composition and process for using an electrochemica l device for the reduction of the oxidized state of phosphorylated or non-phosphorylated nicotinamide adenine dinucleotide to the reduced state in which unwanted pr...
|
|
WO/2017/153936A1 |
This invention provides messenger RNA (mRNA) molecules comprising comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), ...
|
|
WO/2017/155923A1 |
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...
|
|
WO/2017/153186A1 |
The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invent...
|
